• Skip to main content
  • Skip to primary sidebar
  • Home
  • News
  • Events
  • Education
  • Podcast
  • Business Directory
  • Interviews
    • Career spotlight
  • Opinion
    • Professional Dilemmas
  • Patient perspective

Pharmacy in Practice

EDX/20/1154
Date of prep: December 2020

Prescribing information and
adverse events reporting

For healthcare professionals only

MHRA appoint new Chief Executive

24th February 2021 by PIP editor Leave a Comment

 

Dr June Raine has been appointed as the Medicines and Healthcare products Regulatory Agency’s (MHRA) new Chief Executive, having been the interim CEO since 2019.

 

Dr Raine played a crucial part in setting up rolling reviews during the pandemic to ensure the UK was the first in the world to authorise the Pfizer/BioNTech and Oxford University AstraZeneca Covid-19 vaccines.

 

Dr Raine’s work has helped improve patient safety and patient engagement and has helped establish the UK as a world-leading destination for life sciences and the development of new and cutting-edge innovation in medicines and medical devices.

 

Before becoming interim CEO, Dr Raine was Director of Vigilance and Risk Management of Medicines and has worked for MHRA and its predecessor organisations since 1985.

 

Dr Raine qualified in medicine at the University of Oxford and undertook postgraduate research leading to an MSc in pharmacology.

 

After several general medical posts, she joined the then Medicines Division of the Department of Health and has worked in several licensing and patient safety areas including widening the Yellow Card Scheme for patients and the public.

 

Health Minister Lord Bethell said:

 

“It is thanks to Dr Raine’s strong leadership during the pandemic that the UK was the first country in the world to authorise COVID-19 vaccines.

 

“The MHRA is widely regarded as one of the best regulators in the world with the highest standards of safety and I’m delighted to confirm Dr Raine’s appointment as CEO.

 

“I’m confident Dr Raine will build on MHRA’s success during the pandemic to make sure NHS patients are among the first to receive cutting-edge treatments in the future.”

 

This article is being shared under the Open Government Copyright licence.

 

 

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Related

Next article  PSNC negotiate hard after 'extremely challenging year'

Filed Under: News Tagged With: mhra, People

About PIP editor

Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.

Reader Interactions

Begin the discussion right here Cancel reply

Primary Sidebar

Stay connected with us

  • E-mail
  • Facebook
  • Instagram
  • LinkedIn
  • Phone
  • Twitter

Your Pharmacy in Practice Prescription

Categories

Pharmacy in Practice member login

 
 
Forgot Password

Register for our upcoming live Q&A

https://www.youtube.com/watch?v=vVNhKJWCGFA

© 2021 · About Pharmacy In Practice · Site mantained by Mike

This site is for healthcare professionals, please confirm you are a healthcare professional to continue.

YES

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Pharmacy In Practice uses cookies, by continuing to use this site we will assume you are ok with that Find out more.